Celltrion's COVID-19 antibody improves outcomes in phase 2

Celltrion’s anti-SARS-CoV-2 antibody has improved outcomes in patients with mild to moderate COVID-19 in a phase 2/3 clinical trial. The Korean biopharma reported lower rates of progression to severe COVID-19, shortened time to clinical recovery and reduced viral load in patients on the drug.